POZ - ICAAC : ICAAC: Norvir-Boosted Lexiva vs. Reyataz - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
POZ Focus

Back to home » Newsfeed » Conference Coverage » ICAAC

Table of Contents

 
Diary of a Doc: Vaccine Update at ICAAC

ICAAC: Trizivir vs. Reyataz/Combivir

ICAAC: Norvir-Boosted Lexiva vs. Reyataz

Predictive Value of Viral Load Testing Questioned

ICAAC: MK-0518 Potent for Treatment Experienced

ICAAC: More Drug-Resistant HIV?

ICAAC: Prezista and Aptivus on Drug-Resistant HIV

Prezista Women's Study Opens for Enrollment

ICAAC Opens in San Francisco

ICAAC: Predicting Responses to Aptivus or Prezista

ICAAC: MK-0518 Appears Lipid Friendly

ICAAC: Abortion Pill for HIV? Questions Still Remain

 
What You're Talking About
Let's Kick ASS - AIDS Survivor Syndrome (36 comments)

Why I Still (Kinda, Sorta) Go to the Gym (blog) (16 comments)

FDA Approves Gilead’s Hep C Drug Harvoni (via Hep) (9 comments)

Ebola vs. AIDS, Obama vs. Reagan (blog) (8 comments)

Health Care is a Human Right (8 comments)

90 Years Old and HIV Positive (7 comments)
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


emailprint

ICAAC: Norvir-Boosted Lexiva vs. Reyataz

by Tim Horn

October 2, 2006 (AIDSmeds)—Early data from a study comparing Lexiva® (fosamprenavir) to Reyataz® (atazanavir), both combined with low-dose Norvir® (ritonavir), suggest that both drugs have similar effectiveness. The 24-week study results were reported as a late-breaker slide presentation on Friday at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.

Protease inhibitors (PIs) combined with low-dose Norvir have become increasingly popular treatment options in recent years. This is based on a litany of research conducted over the past several years indicating that Norvir boosting can help maximize effectiveness and ease dosing. Kaletra, containing lopinavir and Norvir, remains one of the most widely prescribed boosted PIs.

Other popular PIs, including Lexiva and Reyataz, are frequently boosted with Norvir. But only recently has there been data from clinical trials conducting head-to-head comparisons between boosted PI options. At the International AIDS Conference (IAC) this past summer in Toronto, there was a report from a study suggesting that the effectiveness of Norvir-boosted Lexiva is comparable to Kaletra. And at ICAAC, while no comparison to Kaletra was made, Norvir-boosted Lexiva and Reyataz both appear to be doing well in a clinical trial evaluating the two agents.

Twenty-four week data from the 48-week ALERT study were reported at the conference by Kimberly Smith, MD, of Cook Country Hospital in Chicago and her colleagues. The study has enrolled 106 HIV-positive people starting HIV treatment for the first time. Patients have been randomized to take either Reyataz (300mg) plus Norvir (100mg) once daily or Lexiva (700mg) plus an experimental, lower-than-usual dose of Norvir (100mg, instead of the recommended 200mg) once daily. All patients are also receiving standard doses of once-daily Viread (tenofovir) and Epivir (emtricitabine).

Upon entering the study, the 106 HIV-positive patients enrolled had average viral loads of 79,000 and CD4 (T4 cell) counts of 173.

After 24 weeks, 79% of those in the Lexiva group had viral loads below 50; in the Reyataz group, approximately 83% had viral loads below 50. The difference between the two groups wasn't statistically significant, meaning that it could have been due to chance.

CD4 count improvements were also similar in both groups. There was a 126 CD4 cell gain in the Lexiva group, compared to a 156 gain in the Reyataz group.

As for side effects, some time was spent reviewing changes in cholesterol and triglycerides, as these aren’t significantly affected by Reyataz and are only moderately increased when a Norvir boosted is used. In ALERT, cholesterol levels – including LDL and HDL – increases after 24 weeks were modest and similar in both treatment groups. The only statistically significant difference involved triglyceride levels, which increased by an average of 44 mg/dL in the Lexiva group, compared to an average 6 mg/dL increase in the Reyataz group.

The most notable side effect difference between the two groups was an increase in bilirubin levels (which can cause otherwise harmless yellowing of the eyes, skin, and nails), occurring in 44% of patients taking Reyataz compared to no bilirubin increases in the Lexiva group.

Final results of ALERT, to be reported after 48-weeks of follow-up data have been collected, are expected in early 2007. Until then, Dr. Smith and her colleagues remarked that the interim data suggest comparable efficacy between Norvir-boosted Reyataz and Lexiva.


emailprint

[ Go to top ]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.